Christian Pangratz
Chief Executive Officer at Atriva Therapeutics GmbH
Profile
Christian M.
Pangratz currently works at Atriva Therapeutics GmbH, as Chief Executive Officer from 2023.
Mr. Pangratz also formerly worked at Nektar Therapeutics, as Executive Director-Business Development, sterna biologicals GmbH, as Managing Director, SkyePharma Plc, as Executive Vice President-Business Development, Bayer AG, as Principal, Vectura GmbH, as Chief Business Officer from 2013 to 2014, Pfizer GmbH, as Principal, and Vienna GmbH, as Principal.
Mr. Pangratz received his undergraduate degree and graduate degree from Webster University.
Christian Pangratz active positions
Companies | Position | Start |
---|---|---|
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Chief Executive Officer | 2023-01-14 |
Former positions of Christian Pangratz
Companies | Position | End |
---|---|---|
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Corporate Officer/Principal | 2014-08-31 |
sterna biologicals GmbH
sterna biologicals GmbH Pharmaceuticals: MajorHealth Technology Sterna Biologicals GmbH is a German clinical-stage immunology company founded in 2006. The company is based in Marburg, Germany. The company has successfully completed four phase 2a clinical trials in asthma, ulcerative colitis, COPD, and atopic dermatitis. Sterna is focused on developing novel treatments for type 2 chronic inflammatory diseases. | Chief Executive Officer | - |
SKYEPHARMA PLC | Corporate Officer/Principal | - |
Vienna GmbH
Vienna GmbH Financial ConglomeratesFinance Vienna GmbH operates as an investment firm. The company was founded by Bartolo Vienna in 1984 and is headquartered in Wallhausen, Germany. | Corporate Officer/Principal | - |
Pfizer GmbH | Corporate Officer/Principal | - |
Training of Christian Pangratz
Webster University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
NEKTAR THERAPEUTICS | Health Technology |
BAYER AG | Health Technology |
Private companies | 6 |
---|---|
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |
Pfizer GmbH | |
Vienna GmbH
Vienna GmbH Financial ConglomeratesFinance Vienna GmbH operates as an investment firm. The company was founded by Bartolo Vienna in 1984 and is headquartered in Wallhausen, Germany. | Finance |
SkyePharma Plc
SkyePharma Plc Pharmaceuticals: OtherHealth Technology SkyePharma Plc engaged in the provision of pharmaceutical business. It involved in development and supply of pharmaceutical products. The company was founded by Ian Roderick Gowrie-Smith on August 18, 1910 and was headquartered in London, the United Kingdom. | Health Technology |
sterna biologicals GmbH
sterna biologicals GmbH Pharmaceuticals: MajorHealth Technology Sterna Biologicals GmbH is a German clinical-stage immunology company founded in 2006. The company is based in Marburg, Germany. The company has successfully completed four phase 2a clinical trials in asthma, ulcerative colitis, COPD, and atopic dermatitis. Sterna is focused on developing novel treatments for type 2 chronic inflammatory diseases. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
- Stock Market
- Insiders
- Christian Pangratz